Did you miss "Mad Money" on CNBC? If so, here are some of Jim Cramer's top takeaways.

For his "Executive Decision" segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant Pharmaceuticals International (VRX) , the embattled drugmaker that has seen its shares fall from $262 to lows near $9 before finally finding a bottom. Is Valeant turning the corner? Cramer dove in to find out.

Papa admitted that it has been a very challenging 15 months for Valeant, but noted that they've made great progress in turning things around. He said Valeant has new leadership, including a new CFO and general counsel, and the company has retired an astounding $4.8 billion in debt in just the past year.

All told, Valeant will be making 12 asset divestitures to help fix its balance sheet and Papa said the deals still left to close will represent another $1.2 billion on top of that they've already done. Additionally, these asset sales will not impact the bottom line, as Valeant's pipeline of new drugs will generate the returns the company's shareholders are expecting.

Valeant has also made strides in other areas, including the creation of a patient access and pricing committee, which is helping to ensure that more patients who needs their drugs have access to them.

Cramer said that Papa had exceeded what he thought was possible for Valeant and he reiterated his recommendation.

On Real Money, Cramer looks at which retailers are doing better -- and better yet, which offer investment opportunities. Get his insights with a free trial subscription to Real Money.

Cramer and the AAP team are telling their investment club members to take a closer look at Allergan PLC (AGN) as it relates to the share price of Teva Pharmaceutical Industries Ltd. (TEVA) . Get in on the conversation with a free trial subscription to Action Alerts PLUS.

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

To read a full recap of this episode of "Mad Money," click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

More of What's Trending on TheStreet:

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

If you liked this article you might like

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year